Compare Agilent Technologies Inc (A) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs MakeMyTrip Ltd — how do they compare? Agilent Technologies Inc trades at $129.06 (market cap $37.04B), while MakeMyTrip Ltd trades at $56.23 (market cap $5.57B). The key difference: Agilent Technologies Inc is far larger — about 6.6× MakeMyTrip Ltd's market cap, and Agilent Technologies Inc pays a 0.78% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| A | MMYT | |
|---|---|---|
Market Cap | $37.04B | $5.57B |
Sector | Health | Technology |
52-Week High | $157.20 | $103.21 |
52-Week Low | $110.24 | $36.30 |
Enterprise Value | $38.59B | $6.21B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
MakeMyTrip (MMYT) trades at $57.35, down 1.58% today but showing strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.25 versus $0.1654, continuing a trend of earnings outperformance. Revenue reached $978.34M in 2025 with healthy 73.77% gross margins, though valuation metrics appear elevated with a P/E of 159.17. Analyst sentiment remains strongly positive with 72.73% buy ratings.
The outlook remains favorable given consistent earnings beats and strong travel demand recovery, though high valuation multiples and rising debt-to-asset ratios from 12.13% to 80.57% projected for 2026 present significant risks. Temporary travel disruptions have pressured growth, but platform resilience across hotel and package segments supports the bullish case. Investors should weigh growth potential against valuation concerns and increasing leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
